Fundies. English
Neon Therapeutics, Inc.
EDGAR11 filing records in this dataset, filed from 2018-05-31 to 2020-05-01. Reported financial figures are available; chart coverage varies by period.
- Cash and cash equivalents
- 15 million USD Source
Exact value
15047000 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 29 million shares Source
Exact value
28963858 shares
Reported share-count change
2.23% · 633 thousand shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2020-05-01.
Financial data available through: 2019-12-31.
Coverage by financial measure
- revenue: No compatible figures in this window
- Operating income: 4 of 11 periods available· newest 2019-12-31
- Net income: 4 of 11 periods available· newest 2019-12-31
- Operating cash flow: 4 of 11 periods available· newest 2019-12-31
- Capital expenditure: 4 of 11 periods available· newest 2019-12-31
- Total assets: 3 of 11 periods available· newest 2019-12-31
- Total liabilities: 3 of 11 periods available· newest 2019-12-31
- Current assets: 3 of 11 periods available· newest 2019-12-31
- Current liabilities: 3 of 11 periods available· newest 2019-12-31
- Cash and cash equivalents: 4 of 11 periods available· newest 2019-12-31
- long term debt: No compatible figures in this window
- Shares outstanding: 3 of 11 periods available· newest 2019-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
−USD 2.84 millionPrior period
−USD 76.93 million
–
Current period
−USD 79.78 million
–
Exact inputs and evidence
-79776000 − -76934000 = -2842000 USD
-76934000 USD · 2018-01-01 – 2018-12-31
Inspect prior input Prior source-79776000 USD · 2019-01-01 – 2019-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 9.98 millionPrior period
−USD 63.43 million
–
Current period
−USD 73.41 million
–
Exact inputs and evidence
-73412000 − -63428000 = -9984000 USD
-63428000 USD · 2018-01-01 – 2018-12-31
Inspect prior input Prior source-73412000 USD · 2019-01-01 – 2019-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-66.4%Prior period
USD 3.22 million
–
Current period
USD 1.08 million
–
Exact inputs and evidence
1084000 − 3222000 = -2138000 USD
3222000 USD · 2018-01-01 – 2018-12-31
Inspect prior input Prior source1084000 USD · 2019-01-01 – 2019-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2016 2016-01-01 – 2016-12-31 | −USD 27.43 million Exact valueExact value: -27433000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 24.16 million Exact valueExact value: -24157000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 2.4 million Exact valueExact value: 2396000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 26.55 million Calculation and evidence-24157000 − 2396000 USD Exact free cash flow: -26553000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2017 2017-01-01 – 2017-12-31 | −USD 47.54 million Exact valueExact value: -47536000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 41.28 million Exact valueExact value: -41281000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 3.24 million Exact valueExact value: 3242000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 44.52 million Calculation and evidence-41281000 − 3242000 USD Exact free cash flow: -44523000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2018 2018-01-01 – 2018-12-31 | −USD 76.93 million Exact valueExact value: -76934000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 63.43 million Exact valueExact value: -63428000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 3.22 million Exact valueExact value: 3222000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 66.65 million Calculation and evidence-63428000 − 3222000 USD Exact free cash flow: -66650000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2019 2019-01-01 – 2019-12-31 | −USD 79.78 million Exact valueExact value: -79776000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 73.41 million Exact valueExact value: -73412000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 1.08 million Exact valueExact value: 1084000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 74.5 million Calculation and evidence-73412000 − 1084000 USD Exact free cash flow: -74496000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
11 filings · 665 latest values · 665 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001694187, 1694187, edgar:1694187
Also known as Neon Therapeutics, Inc.